News >

Nivolumab Sustains Survival Benefit in RCC at 3 Years

Jason Harris
Published: Monday, Nov 06, 2017

Dr Padmanee Sharma

Padmanee Sharma, MD, PhD
Nivolumab (Opdivo) reduced the risk of death by 26% compared with everolimus (Afinitor) in patients with previously treated advanced renal cell carcinoma (RCC), according to 3-year follow-up data from the phase III CheckMate-025 study.

The FDA approved nivolumab in November 2015 as a treatment for patients with metastatic renal cell carcinoma following prior antiangiogenic therapy.
Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma (RCC). Bristol-Myers Squibb. Accessed November 6, 2017.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication